← Back to All US Stocks

Legend Biotech Corp (LEGN) Fundamental Analysis & AI Grade 2026

LEGN Nasdaq Pharmaceutical Preparations E9 CIK: 0001801198
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Legend Biotech Corp (LEGN) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

LEGN Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

LEGN vs Healthcare Sector: How Legend Biotech Corp Compares

How Legend Biotech Corp compares to Healthcare sector averages

Net Margin
LEGN 0.0%
vs
Sector Avg 12.0%
LEGN Sector
ROE
LEGN 0.0%
vs
Sector Avg 15.0%
LEGN Sector
Current Ratio
LEGN 0.0x
vs
Sector Avg 2.0x
LEGN Sector
Debt/Equity
LEGN 0.0x
vs
Sector Avg 0.6x
LEGN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Legend Biotech Corp Stock Overvalued? LEGN Valuation Analysis 2026

Based on fundamental analysis, Legend Biotech Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Legend Biotech Corp Balance Sheet: LEGN Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

LEGN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

LEGN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Legend Biotech Corp (CIK: 0001801198)

📋 Recent SEC Filings

Date Form Document Action
Mar 27, 2026 4 xslF345X06/form4-03272026_080347.xml View →
Feb 14, 2024 SC 13G legn13gdec23.txt View →
Jan 29, 2024 SC 13G us52490g1022_012924.txt View →
Feb 9, 2023 SC 13G filing.txt View →
Jul 12, 2021 SC 13G p21-1779sc13g.htm View →

Frequently Asked Questions about LEGN

What is the AI rating for LEGN?

Legend Biotech Corp (LEGN) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are LEGN's key strengths?

Claude: Analysis in progress.

What are the risks of investing in LEGN?

Claude: Analysis in progress.

What is LEGN's revenue and growth?

Legend Biotech Corp reported revenue of N/A.

Does LEGN pay dividends?

Legend Biotech Corp does not currently pay dividends.

Where can I find LEGN SEC filings?

Official SEC filings for Legend Biotech Corp (CIK: 0001801198) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is LEGN's EPS?

Legend Biotech Corp has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is LEGN's fundamental grade?

Based on our AI fundamental analysis in May 2026, Legend Biotech Corp has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is LEGN stock overvalued or undervalued?

Valuation metrics for LEGN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is LEGN's AI grade for 2026?

Our dual AI analysis gives Legend Biotech Corp a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is LEGN's free cash flow?

Legend Biotech Corp's operating cash flow is N/A, with capital expenditures of N/A.

How does LEGN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI